Designation
China's CDE proposes breakthrough status for Lepu's CDH17 ADC MRG007 in colorectal cancer
The proposed designation covers advanced colorectal cancer that has progressed on two or more prior lines of systemic therapy. MRG007 is in a Phase Ib/II combination trial in China and won FDA orphan status in pancreatic cancer last month. ArriVent BioPharma holds rights outside Greater China under a January 2025 license valued at up to $1.207 billion.
Written by Gosset from public sources. Source types: News article. Sources are available to Gosset users. Log in to see them.
